A recent study examined whether changes in screening practices has led to changes in the incidence of advanced and metastatic prostate cancer at diagnosis.
Primary care practitioners should be aware of 3 new FDA approvals that may be useful when treating patients with opioid dependence, prostate cancer, and multiple sclerosis.